Tuesday, January 19th, 2016 - Digital Mantra Group | TrialWire

Auckland, Christchurch, Dunedin, Hamilton and Tauranga | New Zealand - Crohn’s disease is a chronic inflammatory condition of the lining of the gastrointestinal tract. 

The inflammation caused by Crohn's disease often spreads beyond affected areas. 

Crohn's disease can be both painful and debilitating, and sometimes may lead to life-threatening complications. 

This clinical study is testing a novel approach for the treatment of Crohn’s disease by targeting the bacteria, Mycobacterium avium subsp. paratuberculosis (MAP), a potential cause of Crohn's disease. This study is called MAP US.

This study will randomize 270 participants and take place in approximately 120 doctors’ offices in the US, and in Canada, Israel, Australia, New Zealand and Poland.  

Potential candidates will be men and women 18 to 75 years of age with moderately to severly active Crohn’s disease diagnosed more than six months ago.  

The study will involve participation of up to 62 weeks. 

Compensation is  available. 

More information for this study can be found by visiting www.MAPmyCrohns.com.

File Library

Contact Profile

Digital Mantra Group | TrialWire

Digital Mantra Group's TrialWire helps connect health journalists and bloggers with the latest medical research news.  


Digital Mantra Group | TrialWire
W: mapmycrohns.com/NZ/index.html


Crohn's disease, Crohns disease, Chrons disease, crohn's disease, Mycobacterium avium subsp. paratuberculosis (MAP), gut health, inflammation, IBD, Colitis, IBS, Auckland, Christchurch, Dunedin, Hamilton, Tauranga, New Zealand



More Formats